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suggest that PGE2 can either promote myoblast proliferation or differentiation in culture (14) (15) (16) (17) (18) . In the COX-2-knockout mouse model, which lacks PGE2, regeneration is delayed. However, the mechanism by which PGE2 acts could not be established in these studies due to the systemic constitutive loss of COX-2 and consequent nonspecific effects on many cell types (15, 19) . Similarly, muscle recovery after injury was impaired in mice given a COX-2 inhibitor (15) . Additionally, mice treated with nonsteroidal anti-inflammatory drugs (NSAIDs), which block the production of prostaglandins through inhibition of COX-1 and COX-2, exhibited regeneration deficits (20, 21) . Moreover, NSAIDS lead to an attenuation of exercise-induced expansion of human satellite cells in biopsies (20) . Likewise, glucocorticoids, which reduce prostaglandin synthesis by suppressing phospholipase A2, COX-2, and mPGES1 expression, adversely affect the recovery of muscle strength in polymyositis patients (22) . However, because the target of NSAIDs and glucocorticoids are the COX enzymes, this effect could entail a number of prostaglandin subtypes Significance Muscle repair after injury entails an immune response that orchestrates efficacious regeneration. Here we identify Prostaglandin E2 (PGE2) as a crucial inflammatory mediator of muscle stem cells (MuSCs), the building blocks of muscle regeneration. PGE2 is synthesized and secreted into the stem-cell niche in response to injury, leading to robust MuSC proliferation, key to myofiber repair. EP4 is the receptor that mediates PGE2 signaling in MuSCs, and genetically engineered mice that lack EP4 in MuSCs have impaired regeneration. Nonsteroidal anti-inflammatory drugs (NSAIDs), commonly used to treat pain after muscle injury, inhibit PGE2 synthesis, hinder muscle regeneration, and lead to weakened muscles. Importantly, a single treatment of injured muscles with PGE2 dramatically accelerates muscle repair and recovery of strength.
in addition to PGE2 and therefore have pleiotropic effects. Thus, to date, the spatiotemporal effects of PGE2 in muscle regeneration remain unresolved.
In response to injury, PGE2 is transiently induced in muscle tissues. To establish if PGE2 acts directly on MuSCs, the building blocks of muscle regeneration, we generated mice in which the PGE2 receptor, EP4, could be conditionally ablated in MuSCs. In addition, we established transgenic reporter mice that enabled specific tracking of MuSC contribution to regeneration dynamically and sensitively over time by bioluminescence imaging (BLI) after PGE2 delivery. We coupled these models with assays of muscle force and found a direct link between the ability of MuSCs to respond to PGE2 and regeneration, leading to restoration of force. Gain-and loss-of-function experiments revealed that PGE2 signaling acts as a rheostat for MuSC function. Our data suggest that PGE2 profoundly impacts regeneration and has therapeutic promise.
Results

A Surge of PGE2 in Damaged Muscle Tissues Accelerates MuSC
Proliferation. We sought to identify an activator of MuSC function by capitalizing on an inflammatory response that mediates muscle regeneration. Because muscle injury triggers an immediate inflammatory response (5, 7, 8, 23) , we hypothesized that a transiently induced inflammatory modulator could regulate MuSC function and play a crucial role in regeneration. We performed qRT-PCR and detected increased levels of the PGE2, a potent lipid mediator during acute inflammation (11), on isolated MuSCs obtained by dissociating muscle tissue followed by fluorescence activated cell sorting (FACS) (Fig. 1A ). In accordance with receptor expression, we detected a surge in the levels of PGE2 in mouse muscle lysates 3 d after injury by standard paradigms entailing notexin injection or cryoinjury ( Fig. 1 B and C and Fig. S1A ). The concomitant transient up-regulation of its synthesizing enzymes Ptges and Ptges2 was also detected ( Fig. 1D ). Although other cell types within muscles may also produce PGE2 in response to injury such as endothelial cells, inflammatory cells, and fibroadipogenic progenitors (FAPs), the myofibers that circumscribe MuSCs are a source of PGE2, as observed in conditioned medium from dissociated myofibers ( Fig. 1E ). Moreover, upon treatment of myofibers with indomethacin, a NSAID that inhibits COX-2, PGE2 synthesis is markedly reduced (Fig. 1E ). The peak in PGE2 levels coincides temporally with the expansion of MuSCs and the well-documented accumulation of inflammatory cytokines such as TGFβ1, CCL2, IL-10, IL-1β, and TNFα after injury, where MuSC activation and expansion take place (3, 5, 7, 8) . Although PGE2 has previously been implicated in the inflammatory damage response, the cellular and molecular mechanism by which it acts in muscle regeneration has yet to be resolved.
To determine whether PGE2 has a direct effect on MuSC expansion, we assessed the proliferation potential of FACS isolated MuSCs (24) treated with PGE2 (10 ng/mL) in culture. This concentration of PGE2 was selected based on a dose-response assay, which resolved the lowest drug concentration that promotes a robust MuSC proliferation response ( Fig. S1B ). We found that a 1-d exposure to PGE2 in culture induced a sixfold increase in the number of MuSCs relative to controls 1 wk later ( Fig. 1F ). This increase in cell division after PGE2 treatment was also evident by EdU incorporation ( Fig. S1 C and D). Culture of MuSCs in media with charcoal-stripped serum, which is depleted of lipid components including prostaglandins (25) , markedly impeded cell proliferation. Addition of PGE2 rescued this block in proliferation ( Fig. S1E ). Notably, whereas freshly isolated MuSCs expressed relatively high levels of EP4 receptor mRNA, expression progressively declined to negligible levels as the cells gave rise to increasingly differentiated muscle cells in culture. This result suggests that MuSCs are the myogenic cell type most responsive to PGE2 ( Fig. 1A ). We further analyzed the effect of PGE2 at the single cell level by tracking individual MuSCs by time-lapse microscopy analysis in a hydrogel "microwell" platform as previously described (26, 27) ( Fig. 1 G-K and Fig. S1 F and G). Clonal assays can reveal differences that are obscured by analysis of the population as a whole. Data were collected over a 38-h time period and then analyzed using the Baxter Algorithms for Cell Tracking and Lineage Reconstruction (26) (27) (28) . We observed a marked increase in cumulative cell divisions and cell numbers in response to PGE2, spanning five generations for the most robust clones ( Fig. 1 G and H) . The basis for the difference between PGE2-treated cells and vehicle-treated controls is that immediately following PGE2 addition after plating, entry into mitosis is accelerated, which is the cause of the subsequent increased expansion ( Fig. 1 I and J and Fig. S1 F and G). The subsequent exponential increase in cells in both conditions exacerbates the difference at the onset, culminating in almost twice the number of total cells at the end of the 38-h timespan (Fig. S1G ). The concomitant increase in the incidence of larger cell sizes observed after PGE2 treatment ( Fig. 1K ) supports its role in mitotic events (29) .
PGE2 Treatment Augments Muscle Regeneration.
To determine if PGE2 impacted the function of MuSCs in regeneration, we performed in vivo experiments. To monitor the dynamics of regeneration over time in a quantitative manner, we capitalized on a sensitive and quantitative BLI assay we previously developed for monitoring MuSC function after transplantation (24, 26, 27, 30) . MuSCs were isolated from transgenic mice expressing both GFP and luciferase (GFP/Luc mice), and equivalent numbers of MuSCs (250 cells) were coinjected with either PGE2 or vehicle into injured tibilais anteriors (TAs) of NOD-SCID gamma (NSG) mice. PGE2 coinjection enhanced the regenerative capacity of MuSCs by nearly two orders of magnitude compared with controls assessed by BLI. Histological analysis reveals GFP + MuSC engraftment in the niche and GFP + fibers resulting from fusion over the time course ( Fig. 2A and Fig. S2 A and B) . Moreover, following engraftment, a secondary injury elicited a spike in BLI signals of PGE2-treated MuSCs relative to controls, suggesting enhanced stem-cell repopulation ( Fig. 2A) . Notably PGE2 is known to have a relatively short half-life in vivo (31) . Thus, these experiments demonstrate that transient exposure of MuSCs to PGE2 at the time of codelivery to injured muscle suffices to significantly enhance muscle regeneration.
We postulated that delivery of PGE2 alone could increase endogenous MuSC numbers and enhance regeneration, circumventing the need for a cell therapeutic. We reasoned that PGE2 delivered during the early time window immediately after injury could augment the beneficial effects of the innate inflammatory response and PGE2 surge. To test this possibility, muscles of young mice were injured, and 2 d later, we injected a bolus of PGE2 ( Fig. 2B ). We observed a striking increase (65 ± 7%) in endogenous PAX7expressing MuSCs in the classic satellite cell niche beneath the basal lamina and atop myofibers 14 d after injury ( Fig. 2 B and C) . . This change reflects the remodeling of myofiber architecture that accompanies the observed accelerated regeneration, as muscle mass did not increase during this time period ( Fig. S2E ). In addition, we tracked the response to injury and PGE2 of endogenous MuSCs by luciferase expression using a transgenic mouse model, Pax7 CreERT2 ;Rosa26-LSL-Luc ( Fig. 2 F and G) . The BLI data were in agreement with the histological data ( Fig. 2 B and C) . That a single injection of PGE2 after injury could suffice to boost endogenous MuSC numbers and regenerative function leading to this degree of accelerated regeneration was quite unexpected.
EP4 Receptor Mediates PGE2 Signaling to Promote MuSC Proliferation and
Engraftment. PGE2 is known to signal through four G proteincoupled receptors (Ptger1-4; EP1-4) (6, 11), but the expression of these receptors in MuSCs has not previously been reported. An analysis of the transcript levels of the different receptors (Ptger1-4) revealed that 24 h after PGE2 treatment, the most highly expressed receptor in MuSCs is Ptger4 (Fig. 3A ). PGE2-treated MuSCs showed elevated downstream intracellular cAMP levels ( Fig. 3B ), a response associated with EP4 signaling (11) , and in the presence of an EP4 antagonist, ONO-AE3-208, the increased proliferation response induced by PGE2 was blunted ( Fig. 3C ). These data confirm that PGE2 signals through the EP4 receptor to promote proliferation. The specificity of PGE2 for EP4 was most clearly shown by the marked reduction in proliferation of MuSCs lacking the receptor following Cre-mediated conditional ablation of EP4 in MuSCs isolated from EP4 f/f mice ( Fig. 3D and Fig. S3 A-D). A requirement for EP4 in MuSC proliferation was confirmed by tamoxifen treatment of MuSCs isolated from Pax7 CreERT2 :EP4 f/f mice in which Cre-mediated EP4 ablation is under the control of the MuSC-specific Pax7 promoter ( Fig. S3 E and F) . Notably, compensation by other PGE2 receptors does not occur in MuSCs lacking EP4 as expression of EP1, EP2, and EP3 receptors (Ptger1-3) remains low in MuSCs (Fig.  S3G ). Together, these data show that PGE2 and its receptor EP4 are crucial for MuSC proliferation. To determine if EP4 plays a role in MuSC function in vivo, we transplanted luciferase-expressing MuSCs that lacked the EP4 receptor following conditional ablation in culture into injured TAs of NSG mice. The BLI signal that was initially detected progressively declined to levels below the threshold of significance ( Fig. 3E and Fig. S3 A-D). Thus, in the absence of PGE2 signaling via the EP4 receptor, regeneration is impaired.
Transcription Factor Nurr1 Is a Downstream Mediator of PGE2/EP4
Signaling in MuSCs. To perform an unbiased search for mediators of signaling downstream of PGE2 that mediate the enhanced effect of MuSC functions, we performed an RNA-sequencing (RNA-seq) analysis comparing isolated MuSCs treated with vehicle (control) or PGE2 for 24 h (Fig. S4A ). Bioinformatics analyses using Ingenuity Pathway Analysis (IPA) and Metacore software packages revealed that in addition to regulators of PGE2 metabolism, PGE2 treatment of MuSCs led to an increase in molecular and cellular functions consistent with stem-cell expansion, including cAMP signaling, and cell-cycle regulation ( Fig. S4 B and C) . Among the top 200 differentially expressed genes with a nonadjusted P value < 0.05, only 11 transcription factors were identified (Fig. 4A ). Nurr1 was among the few that were differentially expressed. Nurr1 had also previously been shown to mediate PGE2 signaling through cAMP and phospho-CREB to induce cell proliferation in colorectal cancer and neuronal cells (32, 33) . To investigate its putative role as a downstream effector of EP4 signaling in MuSCs, we examined its expression in vivo.
Remarkably, the time window of Nurr1 expression mirrored that of PGE2 in muscle tissue, peaking at day 3 after injury (Figs. 1B and 4B). In culture, PGE2 treatment increased Nurr1 mRNA and protein expression ( Fig. 4 C and D) , and Nurr1 knockdown blunted the effect of PGE2 in inducing MuSC proliferation ( Fig. 4E and Fig. S4D ). To determine the specificity of Nurr1 transcriptional regulation to PGE2mediated EP4 receptor signaling, we ablated the EP4 receptor in Pax7 CreERT2 :EP4 f/f MuSCs by tamoxifen treatment (Fig. S4E ). Nurr1 was not up-regulated after PGE2 treatment in EP4 knockout MuSCs (Fig. 4F ). Expression of Nurr1 was highest in MuSCs and declined at the onset of differentiation of myogenic cells, in accordance with the expression pattern of EP4 ( Fig. 4G ). Together, these data implicate the transcription factor NURR1 as a mediator of PGE2/EP4 signaling that triggers MuSC expansion.
Loss of PGE2 Signaling Impairs Muscle Regeneration and Strength.
To determine if EP4 is required for regeneration in vivo, we used the Pax7 CreERT2 :EP4 f/f mouse model in which EP4 is specifically and conditionally ablated in MuSCs by sequential i.p. tamoxifen injection into mice ( Fig. 5A ). Induction of EP4 ablation was highly efficient in Pax7 + cells in vivo following tamoxifen treatment and injury. Ptger4 mRNA levels detected in sorted MuSCs were 96% lower than in the control ( Fig. 5 A and B) . In the absence of EP4 signaling in MuSCs, we observed an aberrant persistence of immature centrally nucleated regenerating myofibers that express embryonic myosin heavy chain (eMyHC) at day 7 after injury ( Fig.  5 C and E). This evidence of impaired regeneration was corroborated by a shift toward myofibers with diminished myofiber CSA relative to controls at day 21 after injury ( Fig. 5 D and E) . In these experiments, PGE2 can act on other cell types in muscle tissue in the course of regeneration, such as mature myofibers, FAPs, and immune cells; however, these cells were not sufficient to restore the EP4-deficient MuSC functions. These features provide strong evidence that in the absence of EP4 signaling, efficacious muscle regeneration is impeded. We further tested whether the defects in muscle repair stemming from specific loss of EP4 in MuSCs impacted muscle strength. Strikingly, eliminating signaling through EP4 on MuSCs alone led to a 35 ± 6% and 31 ± 4% decrease in twitch and tetanus force, respectively ( Fig. 5 F-H) , without apparent loss of muscle mass (Fig. S5A ). To determine if the absence of PGE2 altered muscle regeneration and strength after injury, we subjected mice to treatment with a NSAID (indomethacin). A single indomethacin injection into tibialis anterior (TA) muscles of a Pax7 CreERT2 ; Rosa26-LSL-Luc mouse model 3 d after injury led to a decline in BLI relative to controls, indicative of an impairment in MuSC expansion and regeneration ( Fig. 5 I and J) . This loss of regenerative capacity after NSAID treatment was accompanied by a substantial 33 ± 7% reduction in twitch force compared with controls ( Fig. 5 K and L and Fig. S5B ). The diminished strength seen upon global muscle inhibition of PGE2 synthesis mirrored that observed in regenerating muscle with MuSC-EP4-specific knockout, suggesting that MuSC expansion accounts for the majority of the PGE2-mediated effects on muscle regeneration.
Discussion
We have discovered that a major effect of PGE2 is to induce muscle stem-cell expansion during muscle regeneration. PGE2 has been implicated as an immunomodulator that acts on neutrophils, mast cells, and macrophages that are crucial to the early inflammatory response after injury. The ensuing cytokine storm is thought to induce MuSC function in regeneration (3, 6, 7, 11) . Studies in whole-body COX-2 KO mice, in which all prostaglandin synthesis was ablated, supported this conclusion (15, 19) . Myoblasts have been proposed as the cell type responsive to PGE2 in culture (14, 16-18, 34, 35) , but these cells perform poorly in regeneration (24) and cannot account for the observed effects. Moreover, other studies implicating PGE2 in regeneration all suffered from pleiotropic effects on a multiplicity of cell types.
MuSCs are crucial to development and regeneration (1-3, 24, 36-38), and their numbers dramatically increase in response to insults that damage the muscles in mice and humans (5, 20, (39) (40) (41) (42) . Injections of MuSCs into injured muscles lead to their exponential increase, whereas injection of their myoblast derivatives results in a decline in numbers, revealing a remarkable distinction in regenerative capacity of these two cell types (24) . Here we show that the major effect of PGE2 during muscle regeneration is on MuSCs and that this effect is direct and mediated by the EP4 receptor. Notably, EP4 is robustly expressed on MuSCs and progressively diminishes to negligible levels on differentiating myoblasts, suggesting that the most responsive myogenic cell type to PGE2 is the MuSC. Mechanistically, once PGE2 engages the EP4 receptor, it activates cAMP and the downstream proliferation-inducing transcription factor Nurr1, leading to accelerated MuSC proliferation (Fig. 6) . Although Nurr1 has been associated in intestinal epithelial cells with induction of proliferation and regeneration by directly blocking the cell cycle inhibitor p21 (Waf1/Cip1) in intestinal epithelial cells (43) , its role in the expansion of stem cells, and particularly MuSCs, has not previously been described. The finding that further substantiates that Nurr1 mediates the onset of MuSC proliferation in vivo is that its levels transiently peak in muscle tissues 3 d after injury, concomitant with the observed surge in PGE2.
We show that MuSC function and engraftment are strictly dependent on PGE2 signaling through its receptor by its conditional and specific ablation of EP4 using two approaches. Ablation of EP4 on MuSCs in vitro followed by transplantation in vivo leads to diminished engraftment evident by BLI. The most striking evidence of a crucial role for EP4 derives from its in vivo ablation of EP4 specifically on endogenous MuSCs, which causes a marked reduction in muscle strength after injury accompanied by a shift toward smaller and more immature myofibers relative to controls ( Fig. 6 ). Thus, in the absence of the EP4 receptor, regeneration by both transplanted and endogenous MuSCs is severely impaired.
The surge in PGE2 after injury is transient. Similarly, acute PGE2 treatment enhances and accelerates muscle regeneration long-term. When freshly isolated MuSCs were coinjected with PGE2 into injured muscles, a boost in muscle repair was evident by BLI. A single ex vivo exposure of hematopoietic stem cells to PGE2 had a similarly pronounced effect on subsequent stem cell expansion and reconstitution of the blood after transplant (44) . Indeed, a single injection of PGE2 alone (without MuSCs) directly into injured muscles led to a striking increase in endogenous MuSC numbers and myofiber sizes that was apparent within 2 wk. The beneficial effects of delivery of the inhibitor of the PGE2-degrading enzyme (15-PGDH) SW033291 on hematopoietic, liver, and colon regeneration are likely due to a similar augmentation of endogenous PGE2 levels (45) . Notably, PGE2 and its analogs have safely been used in patients for more than a decade, for instance to induce labor (46) and to promote hematopoietic stem-cell transplantation (44) . Together with our findings, these studies pave the way for its clinical use in boosting muscle repair after injury.
We show that PGE2 levels act as a rheostat that controls the efficacy of regeneration. Augmentation of the inflammatory PGE2 response to injury leads to accelerated MuSC expansion and muscle regeneration. By contrast, NSAID administration at the time of injury to control pain, a common practice, abrogates that effect, suggesting that PGE2 signaling during this early temporal window is crucial to its beneficial effects. Most striking is our finding that a single PGE2 treatment suffices to rapidly and robustly invoke a MuSC response to enhance regeneration of damaged muscle and restore strength.
Materials and Methods
Mice. We performed all experiments and protocols in compliance with the institutional guidelines of Stanford University Institutional review board (IRB) and Administrative Panel on Laboratory Animal Care (APLAC). We obtained young wild-type C57BL/6 mice from Jackson Laboratory. Double-transgenic GFP/luc mice were obtained as described previously (Jackson Laboratory, Stock 008450) (24) . NSG were obtained from Jackson Laboratory (Stock 0055570). EP4 flox/flox (EP4 f/f ) mice were a kind gift from K. Andreasson, Department of Neurology & Neurological Sciences, Stanford University School of Medicine, Stanford, CA (Jackson Laboratories, Stock 028102) (47) . Doubletransgenic Pax7 CreERT2 ;EP4 f/f were generated by crossing Pax7 CreERT2 mice obtained from Jackson Laboratory (Stock 017763) (48) and EP4 f/f mice. Doubletransgenic Pax7 CreERT2 ;Rosa26-LSL-Luc were generated by crossing Pax7 CreERT2 mice and Rosa26-LSL-Luc obtained from Jackson Laboratory (Stock 005125) (49) . We validated these genotypes by appropriate PCR-based strategies. All mice from transgenic and wild-type strains were of young age (2-4 mo). All experiments were conducted using age-and gender-matched controls and littermates randomly assigned to experimental groups.
For muscle injury, notexin (10 μg·mL −1 ; Latoxan, catalog no. L8104) or cardiotoxin (10 μM; Latoxan, catalog no. L8102) injection or crioinjury was performed into the TA muscle. Details are provided in SI Materials and Methods.
FACS for Mouse MuSCs. We isolated and enriched MuSCs as previously described (24, 26, 27) . Details are provided in SI Materials and Methods.
Flow Cytometric Analysis. We analyzed NURR1 levels by flow cytometry using myogenic progenitors after a 24-h treatment of vehicle (DMSO) or PGE2 (10 ng/mL) or from MuSCs transfected with shSCR or shNurr1 (see Knockdown Assays). We collected cells by incubation with 0.5% trypsin in PBS for 2 min at 37°C. We fixed the cells using 1.6% paraformaldehyde in PBS and then permeabilized them in ice-cold methanol. We then blocked them in staining buffer (0.5% BSA in PBS) for 30 min at room temperature and stained them with a mouse monoclonal anti-Nurr1 (Abcam, catalog no. ab41917, 1:75) primary antibody or anti-mouse IgG control (Jackson ImmunoResearch Laboratories). Then, we stained cells with Pacific Blue-conjugated goat anti-mouse secondary antibody (Thermo Fisher Scientific, catalog no. P-10994, 1:500). We analyzed the cells on a FACS LSR II cytometer using FACSDiva software (BD Biosciences) in the Stanford Shared FACS Facility, purchased using NIH S10 Shared Instrument Grant S10RR027431-01.
MuSC Transplantation. We transplanted 250 freshly isolated MuSCs ( Fig. 2A ) or 1,000 cultured MuSCs (Fig. 3E) into the TA muscles of recipient mice as previously described (24, 26, 27) . Details are provided in SI Materials and Methods.
BLI. We performed BLI using a Xenogen-100 system, as previously described (24, 26, 27, 30) . Details are provided in SI Materials and Methods.
Hydrogel Fabrication. We fabricated polyethylene glycol (PEG) hydrogels from PEG precursors, synthesized as described previously (27) . Details are provided in SI Materials and Methods.
MuSC Culture, Treatment, and Lentiviral Infection. Following isolation, we resuspended MuSCs in myogenic cell culture medium containing DMEM/F10 (50:50), 20% FBS, 2.5 ng·mL −1 fibroblast growth factor-2 (FGF-2 also known as bFGF) and 1% penicillin-streptomycin. We seeded MuSC suspensions at a density of 500 cells per cm 2 surface area. We maintained cell cultures at 37°C in 5% CO 2 and changed medium every other day. For PGE2, EP4 receptor antagonist treatment studies, we added 1-200 ng/mL Prostaglandin E2 (Cayman Chemical) (unless specified in the figure legends, 10 ng/mL was the standard concentration used), and/or 1 μM EP4 antagonist (ONO-AE3-208, Cayman Chemical) to the MuSCs cultured on collagen-coated dishes for the first 24 h. The cells were then trypsinized and cells reseeded onto hydrogels for an additional 6 d of culture. All treatments were compared with their solvent (DMSO) vehicle control. For stripped serum assays, we resuspended isolated MuSCs in stripped serum medium containing DMEM/F10 (50:50), 20% charcoal stripped FBS (Gibco, cat no. 12676011), 2.5 ng·mL −1 bFGF, and 1% penicillin-streptomycin. For these experiments, MuSCs were cultured on hydrogels and vehicle (DMSO), or 10 ng/mL PGE2 (Cayman Chemical) was added to the cultures with every media change (every 2 d). Proliferation (see below) was assayed 7 d later. We performed all MuSC culture assays and transplantations after 1 wk of culture unless noted otherwise.
For EP4 f/f MuSCs studies, we isolated MuSCs as described above (FACS for Mouse MuSCs) and infected all cells with lentivirus encoding EF1α-luc-IRES-GFP (GFP/luc virus) for 24 h in culture as described previously (26) , and a subset of them was coinfected with a lentivirus encoding pLM-CMV-R-Cre (mCherry/Cre virus) for 24 h in culture. pLM-CMV-R-Cre was a gift from Michel Sadelain, Memorial Sloan-Kettering Cancer Center, New York (Addgene plasmid 27546) (50) . We transplanted EP4 f/f MuSCs (1,000 cells) into young (2-4 mo) 18-gy irradiated TAs of NSG recipient mice. For in vitro proliferation assays, EP4 f/f MuSCs were plated on hydrogels after infection and treated for 24 h with vehicle (DMSO) or 10 ng/mL PGE2, and proliferation was assayed 3 d later. Cells were assayed for GFP and/or mCherry expression 48 h after infection using an inverted fluorescence microscope (Carl Zeiss Microimaging). Additionally, we also performed experiments with MuSCs isolated from Pax7 CreERT2 ;EP4 flox/flox or control Pax7 +/+ ;EP4 flox/+ littermates. MuSCs were plated on collagen-coated plates and treated with 1 μM 4-hydroxy tamoxifen or vehicle (95% ethanol) during 48 h and then either passed onto hydrogels to assess proliferation 7 d later or treated with PGE2 or vehicle and collected for analysis. MuSCs are freshly isolated from the mice by FACS and put in culture for a maximum time period of 1 wk; therefore, mycoplasma contamination is not assessed.
Clonal MuSC Proliferation and Fate Analyses. We assayed clonal MuSC proliferation by time-lapse microscopy as previously described (26, 27) . Details are provided in SI Materials and Methods.
Proliferation Assays. To assay proliferation, we used three different assays (hemocytometer, VisionBlue, and EdU). Details are provided in SI Materials and Methods.
Knockdown Assays. For Nurr1 silencing in MuSCs, lentiviruses containing pLKO.1-scramble shRNA (shSCR) and pLKO.1-Nurr1 shRNA (Mission shRNA, TRCN0000026029, Sigma) were produced in 293T cells using the packaging plasmids pLP1, pLP2, and pLP/VSVG (Invitrogen) by cotransfecting all plasmids using FuGENE-6 (Promega) according to the manufacturer's protocol. Cells were plated the day before infection, and supernatants were collected every 12 h for 2 d from 293T cells. Freshly sorted MuSCs were seeded on collagen-coated plates for 24 h and were then infected with the lentiviruses. Forty-eight hours after, cells were passed onto hydrogels and treated with PGE2 or vehicle (DMSO) for 24 h. Proliferation was assayed 7 d later.
Quantitative RT-PCR. We isolated RNA from MuSCs using the RNeasy Micro Kit (Qiagen). For muscle samples, we snap-froze the tissue in liquid nitrogen, homogenized the tissues using a mortar and pestle, followed by syringe and needle trituration, and then isolated RNA using TRIzol (Invitrogen). We reverse-transcribed cDNA from total mRNA from each sample using the SensiFAST cDNA Synthesis Kit (Bioline). We subjected cDNA to RT-PCR using SYBR Green PCR Master Mix (Applied Biosystems) or TaqMan Assays (Applied Biosystems) in an ABI 7900HT Real-Time PCR System (Applied Biosystems). We amplified samples at 95°C for 10 min and then 40 cycles at 95°C for 15 s and 60°C for 1 min. To quantify relative transcript levels, we used 2 −ΔΔCt to compare treated and untreated samples and expressed the results relative to Gapdh. For SYBR Green qRT-PCR, we used the following primer sequences: Gapdh, forward 5′-TTCACCACCATGGAGAAGGC-3′, reverse 5′-CCCTTTTG-GCTCCACCCT-3′; Ptges, forward 5′-GCTGTCATCACAGGCCAGA-3′, reverse 5′-CTCCACATCTGGGTCACTCC-3′; Ptges2, forward 5′-CTCCTACAGGAAAGT-GCCCA-3′, reverse 5′-ACCAGGTAGGTCTTGAGGGC-3′; Ptger1, forward 5′-GT-GGTGTCGTGCATCTGCT-3′, reverse 5′ CCGCTGCAGGGAGTTAGAGT-3′; and Ptger2, forward 5′-ACCTTCGCCATATGCTCCTT-3′, reverse 5′-GGACCGGTGG-CCTAAGTATG-3′. In Vivo Muscle Force Measurement. Mice were injured as described in Muscle Injury. Force measurements were on the TA muscles at day 14 after injury based on protocols published previously (26, 51) . Details are provided in SI Materials and Methods.
RNA-Seq. For RNA-seq, α7-integrin + CD34 + MuSCs were isolated as described above, seeded on collagen-coated plates, treated a day later with PGE2 or vehicle (DMSO), and processed after 24 h of treatment. RNA was isolated using Qiagen RNAEasy Micro kit from 5,000-10,000 cells and cDNA generated and amplified using NuGEN Ovation RNA-Seq System v2 kit. Libraries were constructed from cDNA with the TruSEQ RNA Library Preparation Kit v2 (Illumina) and sequenced to 30-40 × 10 6 1 × 75-bp reads per sample on a HiSEQ 2500 from the Stanford Functional Genomics Facility, purchased using NIH S10 Shared Instrument Grant S10OD018220.
RNA-Seq Analysis. For the RNA-Seq analysis, RNA sequences were aligned against the Mus musculus genome using STAR (52) . RSEM (53) was used for calling transcripts and calculating transcripts per million (TPM) values as well as total counts. A counts matrix containing the number of counts for each gene and each sample was obtained. This matrix was analyzed by DESeq to calculate statistical analysis of significance (54) of genes between samples.
Immunofluorescence and Histology. We collected and prepared recipient TA muscle tissues for histology as previously described (26, 27) . For mouse injury assays, we incubated transverse sections with Rabbit polyclonal anti-PGE2 (abcam, catalog no. ab2318, 1:100), rat polyclonal anti-Laminin (Clone A5) (EMD Millipore, catalog no. 05-206, 1:200), mouse monoclonal anti-Pax7 (Santa Cruz, catalog no. sc-81648, 1:50), AlexaFluor 647-conjugated wheat germ agglutinin (WGA) antibody (W32466, Thermo Fisher Scientific), rabbit polyclonal anti-GFP (A11122, Thermo Fisher Scientific, 1:500), and mouse monoclonal anti-eMyHC (DSHB, catalog no. F1.652, 1:10) primary antibodies and then with AlexaFluor secondary antibodies (Jackson ImmunoResearch Laboratories, 1:500). We counterstained nuclei with DAPI (Invitrogen).
Image Analysis. We acquired images with an AxioPlan2 epifluorescent microscope (Carl Zeiss Microimaging) with Plan NeoFluar 10×/0.30 N.A. or 20×/0.75 N.A. objectives (Carl Zeiss) and an ORCA-ER digital camera (Hamamatsu Photonics) controlled by the SlideBook (3i) software or with a KEYENCE BZ-X700 all-in-one fluorescence microscope (Keyence) with 20×/0.75 N.A. objectives. The images were cropped using Adobe Photoshop with consistent contrast adjustments across all images from the same experiment. The image composites were generated using Adobe Illustrator. We analyzed the number of PAX7-positive cells using the MetaMorph Image Analysis software (Molecular Devices) and the fiber area using the Baxter Algorithms for Myofiber Analysis that identified the fibers and segmented the fibers in the image to analyze the area of each fiber. For PAX7 quantification, we examined serial sections spanning a depth of at least 2 mm of the TA. For fiber area, the entire cross-section of the TA with the largest injured area was captured and stitched using the Keyence Analysis Software. Data capture and analyses were blinded. The researchers performing the imaging acquisition and scoring were unaware of treatment condition given to the sample groups analyzed.
Statistical Analysis. We performed cell culture experiments in at least three independent experiments where three biological replicates were pooled in each. In general, we performed MuSC transplant experiments in at least two independent experiments, with at least 3-5 total transplants per condition. We used a paired t test for experiments where control samples were from the same experiment in vitro or from contralateral limb muscles in vivo. A nonparametric Mann-Whitney test was used to determine the significance difference between vehicle-treated vs. PGE2-treated groups using α = 0.05. ANOVA or multiple t test was performed for multiple comparisons with significance level determined using Bonferroni correction or Fisher's test as indicated in the figure legends. Unless otherwise described, data are shown as the mean ± SEM. Differences with P value < 0.05 were considered significant (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001).
